4 unchanged sentences
Holders of Record
−Removed: As of the close of business on February 25, 2022, there were 55 stockholders of record of our common stock.
+Added: As of the close of business on March 5, 2023, there were 28 stockholders of record of our common stock.
The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.
5 unchanged sentences
Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.
−Removed: Use of Proceeds from Registered Securities
−Removed: Our initial public offering of common stock was effected under a Registration Statement on Form S-1 (File No.
−Removed: 333-238146), which was declared effective by the SEC on May 11, 2020.
−Removed: There has been no material change in the use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) and other periodic reports previously filed with the SEC
Recent Sales of Unregistered Securities
−Removed: On June 5, 2020, we consummated a concurrent private placement for shares of our common stock in connection with the consummation of our initial public offering.
−Removed: Novartis Institutes for Biomedical Research, Inc., our strategic partner and one of our existing stockholders has purchased $10.0 million in shares of our common stock at $16.00 per share.
Issuer Purchases of Equity Securities
−Removed: Use of Proceeds from our Public Offering of Common Stock
−Removed: In June 2020, our Registration Statement on Form S-1 (No.
−Removed: 333-2381146) was declared effective by the SEC pursuant to which we issued and sold an aggregate of 10,350,000 shares of common stock (inclusive of 9,000,000 shares of common stock and 1,350,000 shares of common stock pursuant to the underwriters’ exercise of their over-allotment option) at a public offering price of $16.00 per share for aggregate net cash proceeds of $148.3 million, after deducting underwriting discounts, commissions and offering costs.
−Removed: No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.
−Removed: The sale and issuance of 10,350,000 shares closed on June 5, 2020.
−Removed: Citigroup Global Markets Inc., Cowen and Company, LLC and Piper Sandler & Co.
−Removed: acted as joint book-running managers for the offering.
−Removed: There has been no material change in the planned use of proceeds from our initial public offering from that described in the Prospectus.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.